Dynacare, Brampton, Ontario, Canada.
DynaLIFE Medical Labs, Edmonton, Alberta, Canada; Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada.
Can J Cardiol. 2022 Aug;38(8):1180-1188. doi: 10.1016/j.cjca.2022.03.019. Epub 2022 Apr 1.
There is limited guidance on laboratory reporting and interpretation of lipids and lipoproteins used in cardiovascular risk stratification. This contributes to inconsistencies in lipid reporting across clinical laboratories. Recently, the Canadian Cardiovascular Society (CCS) published the 2021 CCS guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult. A subcommittee of the Working Group on Reference Interval Harmonization of the Canadian Society of Clinical Chemists has developed harmonized lipid reporting recommendations that are aligned with the 2021 CCS guidelines, to improve the standardization of lipid assessment and clinical decision-making. The proposed harmonized lipid reporting recommendations were critically reviewed by a broad range of laboratory and clinical experts across Canada. Feedback from approximately 30 expert reviewers was reviewed by the Working Group on Reference Interval Harmonization lipid subcommittee, and consensus decisions were incorporated into the 2021 harmonized lipid reporting recommendations. In this position statement, we provide 6 recommendations for laboratory reporting of lipid parameters. These recommendations include implementing the new National Institutes of Health equation to replace the Friedewald equation for calculating low-density lipoprotein cholesterol, offering lipoprotein (a), either as an in-house or send-out test, and using assays that report lipoprotein (a) in molar units (nmol/L). We also developed a harmonized lipid reporting format with interpretive comments that includes flagging results based on screening patients using treatment decision thresholds in a primary prevention setting. Overall, harmonized lipid reporting will help bridge the gap between clinical guideline recommendations and clinical laboratory reporting and interpretation, and will improve cardiovascular risk assessment across Canada.
关于用于心血管风险分层的脂质和脂蛋白的实验室报告和解释,目前仅有有限的指导意见。这导致了临床实验室之间的脂质报告存在不一致性。最近,加拿大心血管学会(CCS)发布了 2021 年 CCS 血脂异常管理指南,用于预防成年人的心血管疾病。加拿大临床化学学会参考区间协调工作组的一个小组委员会制定了与 2021 年 CCS 指南一致的协调脂质报告建议,以改善脂质评估和临床决策的标准化。这些拟议的协调脂质报告建议由加拿大各地的广泛的实验室和临床专家进行了严格审查。工作组参考区间协调脂质小组委员会审查了大约 30 名专家评审员的反馈意见,并将共识决定纳入了 2021 年协调脂质报告建议。在这份立场声明中,我们提出了 6 条关于脂质参数实验室报告的建议。这些建议包括实施新的美国国立卫生研究院方程来替代计算低密度脂蛋白胆固醇的 Friedewald 方程,提供脂蛋白(a),无论是内部检测还是外送检测,并使用以摩尔单位(nmol/L)报告脂蛋白(a)的检测方法。我们还开发了一个协调的脂质报告格式,带有解释性评论,可以根据在初级预防环境中使用治疗决策阈值对患者进行筛查来标记结果。总体而言,协调脂质报告将有助于弥合临床指南建议与临床实验室报告和解释之间的差距,并将改善加拿大的心血管风险评估。